Matthew Hammond

Dr. Hammond is a Principal on the Investment Team at RA Capital Management. He works on both public and private investments across therapeutic areas. Dr. Hammond holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA in Finance from the University of Connecticut. He is currently a board observer at Akouos, Imara Therapeutics, and Imbria Pharmaceuticals. He previously served as a board observer at Calimmune, Crinetics Pharmaceuticals, Eidos Therapeutics, Precision Biosciences, Solid Biosciences, and Stoke Therapeutics.